Navigation Links
ViaCyte, Inc., Receives Three Additional U.S. Patents, Supporting its Development of a Stem Cell Derived Treatment for Diabetes
Date:5/5/2010

SAN DIEGO, May 5 /PRNewswire/ -- ViaCyte, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today that it has received three additional U.S. Patents:

On April 13, the Company was granted U.S. Patent 7,695,963, entitled "Methods for Increasing Definitive Endoderm Production".  Methods described in this patent can improve the yield in manufacturing of definitive endoderm and also cells derived from it.

On April 13, the Company was also granted U.S. Patent 7,695,965, entitled "Methods of Producing Pancreatic Hormones".  This patent describes treatment of diabetes with pancreatic progenitor cells derived from human pluripotent stem cells, which develop and mature in vivo to secrete insulin in response to blood glucose levels.  The '965 patent builds on the Company's earlier U.S. Patent 7,534,608, which issued in May 2009.

On April 27, the Company was granted U.S. Patent 7,704,738, entitled "Definitive Endoderm".  The patent has claims covering a method of producing definitive endoderm.  This method has been widely adopted in the field.  It builds on the Company's landmark U.S. Patent 7,510,876, which issued in March 2009.

These new patents add substantially to the Company's U.S. patent estate.  The Company also has a growing number of patents granted outside the United States.  These patents further underscore ViaCyte's leadership position in developing stem cell based therapies for diabetes.  The Company has focused on this development for almost ten years and is increasingly recognized for its science and IP as a result of this focus.

About ViaCyte, Inc.

ViaCyte (formerly Novocell, Inc.) is a preclinical therapeutic company focused on diabetes.  Our therapy is based on pancreatic beta cell progenitors (Pro-Islet™) derived from human pluripotent stem cells.  These cells are implanted using a durable and retrievable encapsulation device.  Once implanted and matured, these cells secrete insulin in response to blood glucose levels. The Company's goal is long term insulin independence without immune suppression, and without hypoglycemia and other diabetes-related complications.

ViaCyte is a private company headquartered in San Diego, California, with additional operations in Athens, Georgia.  The Company is funded in part through the support of the California Institute for Regenerative Medicine.

This news release may contain forward-looking statements made pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE ViaCyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Patient Safety Technologies, Inc., Contracts to Implement the Safety-Sponge(TM) System at The Mount Sinai Hospital in New York
2. OMNIlife science, Inc., Announces U.S. Distribution Agreement with SERF-Dedienne Sante of France for its ION free Large Diameter Head Dual Mobility Acetabular Cup System
3. NeoMatrix, Inc., Awarded New Technology Agreement by Novation for HALO(R) Breast Pap Test
4. Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive
5. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
6. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
7. Nyer Medical Group, Inc., Announces Agreements to Sell Certain Eaton Apothecary Assets to Walgreens and Sell Operating Subsidiarys Stock to Investors
8. BioStorage Technologies, Inc., Accelerates European Expansion with Opening of New German Facility
9. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
10. CardioVascularCS.Org, a division of EndoVascular Forum, Inc., Partners with Complex Interventional Cardiovascular Therapy (CICT) to Extend Electronic Medical Care Advancement
11. CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
Breaking Medicine News(10 mins):